Report date: Wednesday, July 15, 2026, before the market opens
Conference call: 10:00 a.m. ET
Fiscal period: Quarter and year ended May 31, 2026
Cintas enters earnings with strong operating momentum but a demanding setup. The company’s last update featured 8.2% organic growth, record gross margins and another guidance increase. However, current consensus already sits near the top of management’s implied fourth-quarter range.
The likely stock reaction will therefore depend less on whether CTAS beats Q4 EPS by a penny and more on three issues:
The pending UniFirst acquisition adds a second layer. Investors will want reassurance on regulatory timing, financing and integration economics, although management may limit commentary while the FTC review is ongoing.
| Metric | Q4 FY2025 actual | Q4 FY2026 expectation | Implied growth |
|---|---|---|---|
| Revenue | $2.668B | ~$2.87B–$2.88B | ~7.6%–8.0% |
| Adjusted EPS | $1.09 | ~$1.24 | ~14% |
| Full-year revenue | $10.34B | ~$11.23B | ~8.6% |
| Full-year adjusted EPS | $4.40 | ~$4.89 | ~11% |
Published estimates vary slightly, but the prevailing consensus is approximately $2.87 billion–$2.88 billion of revenue and $1.24 of adjusted EPS. (zacks.com)
After nine months, Cintas had generated $8.360 billion of revenue and $3.65 of diluted EPS. Management’s full-year guidance of $11.21 billion–$11.24 billion and adjusted EPS of $4.86–$4.90 therefore implies:
Consensus is consequently at or near the top end of management’s revenue range and toward the upper end of its EPS range. That makes an in-line result less compelling than it might initially appear. Cintas’ guidance excludes the effect of UniFirst and excludes an estimated $0.03–$0.04 per share of FY2026 transaction costs. (cintas.com)
Cintas posted 8.9% reported and 8.2% organic growth in Q3. The underlying composition was healthy:
Management previously indicated that the Q4 guidance implied approximately 7.6% organic growth, down modestly from Q3. That would still be an excellent outcome given a 9.0% organic-growth comparison in the prior-year quarter.
The main comparison issue is First Aid and Safety. That business grew 18.5% organically in Q4 FY2025, helped by unusually strong AED-related training activity. Uniform Direct Sale also had a strong and potentially difficult-to-repeat prior-year quarter.
What would be encouraging:
Warning signs:
Cintas has said retention remains around 95%, pricing is running at its historical 2%–3% level and new business and cross-selling have been improving. Those indicators will be more informative than reported revenue alone. (dafinchi.ai)
Q3 gross margin reached an all-time high of 51.0%, up 40 basis points year over year. All three route-based businesses posted record gross margins, and operating margin was 23.2%. Excluding a prior-year property gain, operating margin expanded approximately 40 basis points. (cintas.com)
The fourth quarter is normally less favorable seasonally: gross margin was 49.7% in Q4 FY2025. Investors should not expect a simple repeat of Q3’s 51%, but they should expect continued year-over-year progress if Cintas’ operational initiatives are working.
Key puts and takes include:
Positive
Negative
Energy represented 1.7% of Q3 revenue. Management characterized fuel as manageable and included higher expected costs in guidance, but the inflationary backdrop has become more volatile. (fortune.com)
A satisfactory print would combine approximately 8% revenue growth with operating-income growth at least as fast as revenue. A stronger result would show another 20–40 basis points of underlying operating-margin expansion.
The initial FY2027 outlook should carry more weight than the backward-looking quarter. Current consensus is approximately:
That implies roughly 7%–7.5% revenue growth and approximately 11% EPS growth from the expected FY2026 base. (boursorama.com)
A constructive standalone guide would probably include:
One potential FY2027 headwind is the Fire Protection SAP implementation. Management previously suggested that a full-year rollout could represent roughly 100 basis points of margin pressure within that segment, although the actual FY2027 effect should depend on implementation timing.
Investors should also distinguish between standalone guidance and any merger assumptions. Because UniFirst has not closed and regulatory timing remains uncertain, Cintas is likely to exclude UniFirst from its formal outlook and provide separate transaction commentary.
Cintas agreed to acquire UniFirst for approximately $5.5 billion, paying $155 in cash plus 0.7720 CTAS shares for each UniFirst share. Management is targeting approximately $375 million of annual operating-cost synergies within four years, with the transaction expected to become EPS-accretive by the end of the second full year following closing. Expected leverage at closing is approximately 1.5 times debt to EBITDA. (cintas.com)
The shareholder vote is complete, but the FTC issued a Second Request on June 11, 2026, extending the antitrust review. Cintas continues to target a closing in the second half of calendar 2026. (sec.gov)
Questions investors will want addressed include:
Management may decline to discuss the FTC process in detail. Even so, simply reaffirming the closing window and synergy framework would be incrementally reassuring.
At approximately $184 per share, CTAS trades near 34 times the FY2027 consensus EPS estimate. That remains a premium valuation, even after the stock’s pullback over the past year. (tradewithmaya.com)
The multiple reflects Cintas’ unusually consistent growth, high retention, recurring route-based revenue and strong capital returns. But it also means that merely meeting expectations may not be sufficient.
Cintas’ fundamental setup remains strong: recurring revenue, record retention, steady pricing, significant cross-selling potential and proven operational execution. The challenge is that consensus already assumes the company lands near the top of its Q4 guidance.
The most important figure tomorrow may not be reported EPS. It will be the combination of organic growth, incremental margin and the initial FY2027 outlook. A clean Q4 beat accompanied by another double-digit EPS-growth guide would reinforce the premium-compounder thesis. Conversely, an in-line quarter paired with cautious FY2027 guidance could pressure the shares, particularly at a roughly 34-times forward multiple.